Provided by Tiger Trade Technology Pte. Ltd.

EVEREST MED

36.840
+5.74018.46%
Volume:33.98M
Turnover:1.18B
Market Cap:13.04B
PE:-41.39
High:37.260
Open:30.460
Low:30.380
Close:31.100
52wk High:75.150
52wk Low:22.700
Shares:354.00M
HK Float Shares:354.00M
Volume Ratio:0.84
T/O Rate:9.60%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.890
ROE:-1.18%
ROA:-1.06%
PB:2.14
PE(LYR):-41.39
PS:4.64

Loading ...

Everest Med: Issued Shares Reach 353.84 Million After July Option Exercises; Public Float Remains Adequate

Bulletin Express
·
Aug 06

Everest Medicines Updates Financial Calendar with Interim Results, Investor Call Scheduled

Reuters
·
Aug 05

Everest Medicines Board to Review Interim Results for Six Months Ended June 30, 2026

Reuters
·
Aug 05

Everest Medicines CFO to Join Morgan Stanley Biotech Without Borders Fireside Chat

Reuters
·
Jul 27

Movement Alert|Everest Medicines Rises 5.18% in Regular Trading, Biotech Sector Rebounds After Prior Selloff

Market Focus
·
Jul 20

EVEREST MED Grants 473,000 Share Options and 1.3985 Million Awards

Stock News
·
Jul 17

Everest Medicines Grants 1,398,527 Share Awards Under 2026 Share Scheme

Reuters
·
Jul 17

Movement Alert|Everest Medicines Falls 7.83% in Regular Trading, Biotech Sector Selloff Drags Down Individual Stocks

Market Focus
·
Jul 17

Three Core Emergency Drugs from Everest Med Included in China's 2026 National Essential Medicines List

Deep News
·
Jul 16

Movement Alert|Everest Medicines Rises 6.67% in Regular Trading, EVER001 Licensing Deal Closure and Biotech Sector Rally Drive Gains

Market Focus
·
Jul 15

EVEREST MED seals US$1.14 billion licensing and collaboration deal with Travere Therapeutics

Bulletin Express
·
Jul 07

EVEREST MED Completes Transaction with Travere Therapeutics for Exclusive Licensing and Collaboration Agreement

Stock News
·
Jul 07

Everest Medicines Closes Exclusive Licensing, Collaboration Deal with Travere for Us$112.5 Million Upfront

Reuters
·
Jul 07

Everest Med Adds 6,900 Shares in June; Total Issued Shares Reach 353.83 Million

Bulletin Express
·
Jul 07

Movement Alert|Everest Medicines Falls 5.03% in Regular Trading, Trading at HK$27.2

Market Focus
·
Jul 07

Movement Alert|Everest Medicines Intraday Rise 7.05%, Multiple BD Catalysts Combined with Biotech Sector Momentum

Market Focus
·
Jul 06

Movement Alert|Everest Medicines Intraday Rise 8.16%, PCSK9 Inhibitor BLA Acceptance Combined with Multiple Positive Catalysts

Market Focus
·
Jul 02

From Asset Portfolio to Cash Flow Generation: The Core Rationale for Reassessing Everest MED

Deep News
·
Jun 30

Vikail Pharma’s Vicagrel Antithrombotic Drug Wins China Filing Acceptance for Market Approval

Reuters
·
Jun 30

Everest Medicines Shareholders Adopt 2025 Audited Financial Statements at AGM

Reuters
·
Jun 26